LRRK2 and Parkinson disease: An increased understanding of the etiopathogenesis of PD has led to the development of potential neuroprotective and/or disease-modifying therapies, including gene therapy37, immunotherapy, glucagon-like peptide 1 (GLP1) receptor agonists, iron chelators38, specific glucocerebrosidase (GBA) modifiers39 and leucine-rich repeat kinase 2 (LRRK2) inhibitors40.